Trump Administration To Close Loophole And Codify Medicare Drug Price Regulations

The Trump administration is moving to slam shut a loophole that drugmakers have used to dodge Medicare price negotiations—by simply adding a new active ingredient to an existing drug. This regulatory crackdown, announced on July 3, 2026, simultaneously codifies earlier rules that gave the government power to haggle over the cost of top-selling medications under Medicare Part D. The move is the latest salvo in a long-running battle over drug pricing that has pitted the pharmaceutical industry against both political parties.

The administration is finalizing a regulation that explicitly classifies any drug with a new active ingredient as still subject to Medicare negotiation unless that ingredient provides a major clinical improvement. Previously, drugmakers exploited a conceptual gap: if they spiked a blockbuster drug with a novel active ingredient, they could argue the resulting product was a new chemical entity not covered by the negotiation list. The loophole allowed manufacturers to switch billions of dollars in sales from negotiated to non-negotiated status, frustrating Medicare cost-savings goals.

Why now? The Inflation Reduction Act (IRA) of 2022 gave Medicare the authority to negotiate prices on certain drugs for the first time, a landmark shift in U.S. health policy. But the law left room for interpretation on what qualifies as a new drug. Drugmakers quickly began reformulating their most expensive products—for example, combining an existing active ingredient with a slightly different molecule—to skirt the negotiation list. By 2025, the Department of Health and Human Services had identified at least a dozen drugs where manufacturers had used this tactic, potentially shielding billions in revenue.

The Trump administration’s new rule closes that gap authoritatively. It stipulates that only drugs approved under a new drug application (NDA) for a distinctly different active ingredient that offers a significant therapeutic advantage can be considered new for negotiation purposes. The rule also codifies existing procedural regulations on how Medicare selects drugs for negotiation, including timelines, data submission requirements, and appeal rights. This codification makes it harder for future administrations to reverse course without a formal rulemaking process.

Industry reaction has been swift. The Pharmaceutical Research and Manufacturers of America (PhRMA) stated that the rule could chill innovation, as it disincentivizes incremental improvements. Patient advocacy groups, meanwhile, applauded the move, arguing it protects seniors from price hikes that had no real medical justification. The rule is expected to affect drugs used by millions of Medicare beneficiaries, including treatments for diabetes, heart disease, and rheumatoid arthritis.

Analysts note that this is a rare instance of a Republican administration expanding government intervention in drug pricing—a policy more typical of Democrats. It reflects a political calculus: controlling Medicare costs appeals to both fiscal conservatives and senior voters. The move also aligns with Trump’s broader deregulatory narrative by simplifying a patchwork of guidance into clear, enforceable rules.

The next milestone is a 60-day public comment period, after which the rule could take effect as early as late 2026. The first drugs selected under the new, tighter criteria are likely to be announced in 2027. If successful, the loophole closure could save Medicare tens of billions of dollars over a decade—and set a precedent that other nations may follow.